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Loss- and gain-of-function mutations of the X-linked
gene MECP2 (methyl-CpG binding protein 2) lead
to severe neurodevelopmental disorders in humans,
such as Rett syndrome (RTT) and autism. MeCP2
is previously known as a transcriptional repressor
by binding to methylated DNA and recruiting histone
deacetylase complex (HDAC). Here, we report that
MeCP2 regulates gene expression posttranscrip-
tionally by suppressing nuclear microRNA process-
ing. We found that MeCP2 binds directly to DiGeorge
syndrome critical region 8 (DGCR8), a critical compo-
nent of the nuclear microRNA-processing machin-
ery, and interferes with the assembly of Drosha
and DGCR8 complex. Protein targets of MeCP2-
suppressed microRNAs include CREB, LIMK1, and
Pumilio2, which play critical roles in neural develop-
ment. Gain of function of MeCP2 strongly inhibits
dendritic and spine growth, which depends on the
interaction of MeCP2 and DGCR8. Thus, control of
microRNA processing via direct interaction with
DGCR8 represents a mechanism for MeCP2 regula-
tion of gene expression and neural development.
INTRODUCTION
Loss-of-function mutations in methyl-CpG binding protein 2
(MECP2) gene are primary causes for Rett syndrome (RTT)
(Amir et al., 1999; reviewed in Chahrour and Zoghbi, 2007),
whereas the duplications of MECP2-containing loci may lead
to autism spectrum disorders in human (Ramocki et al., 2009).
Therefore, the dose of MeCP2 protein is critical for the proper
development and function of the central nervous system
(CNS). MeCP2 was found to primarily bind to methylated CpG
islands and acts as a transcriptional repressor by recruiting
histone deacetylase complex (HDAC) (Lewis et al., 1992; Nan
et al., 1993, 1998; reviewed in Guy et al., 2011). MeCP2 has
been shown to play critical roles in regulating gene expression
transcriptionally, including brain-derived neurotrophic factorDevelo(BDNF) and other genes important for the proper function of
the CNS (Chen et al., 2003; Martinowich et al., 2003; Tao et al.,
2009; Zhou et al., 2006). Furthermore, MeCP2 was found to
regulate synaptic homeostasis by transcriptionally repressing
GluA2 expression in an activity-dependent manner (Qiu et al.,
2012). Posttranslational modifications of MeCP2 play critical
roles in regulating neural development (Cohen et al., 2011). For
example, the activity-dependent phosphorylation of Serine 421
(Ser421) of MeCP2 is critical for regulating the recruitment of
MeCP2 on DNA and expression of target genes such as BDNF
(Cohen et al., 2011; Zhou et al., 2006), and the interaction
between MeCP2 and the nuclear receptor corepressor complex
(NCoR) is regulated by an activity-dependent phosphorylation of
Thr308 of MeCP2 (Ebert et al., 2013; Lyst et al., 2013).
Transcriptome-wide studies revealed that expression of many
genes is repressed in the brain ofmecp2 null mice, suggesting a
positive role forMeCP2 in gene regulation (Chahrour et al., 2008).
An alternative possibility is that MeCP2 controls posttranscrip-
tional regulators, e.g., microRNAs (miRNAs), which are known
to specifically suppress generation of many proteins that are
important for cell proliferation, development, and tumorigenesis
(Bartel, 2004; Bushati and Cohen, 2007; Fire et al., 1998). The
biogenesis of miRNAs begins with the transcription of the pri-
mary miRNAs from the genome, followed by its processing
through Drosha/DiGeorge syndrome critical region 8 (DGCR8)-
containing nuclearmachinery and cytosolic Dicer complex (Denli
et al., 2004; Gregory et al., 2004; Han et al., 2004; Lee et al.,
2003). It was reported recently that miRNA expression profile
was altered in the brain of mecp2 null mouse due to the tran-
scriptional repression function of MeCP2 (Szulwach et al.,
2010; Urdinguio et al., 2010; Wu et al., 2010). Whether MeCP2
may participate in the miRNA processing directly other than
the transcription process is unknown.
In this study, we found that MeCP2 regulates gene expres-
sion posttranscriptionally by regulating nuclear miRNA process-
ing directly. We showed that MeCP2 directly interacts with
DGCR8, a critical component of the nuclear miRNA-processing
complex, through its C-terminal domain. The phosphorylation
of Ser80 of MeCP2 is crucial for binding to DGCR8, which is
rapidly dephosphorylated by neuronal calcium signaling. Inter-
estingly, the phosphorylation of Ser80 regulates an intramolecu-
lar interaction switch of MeCP2, which leads to an ‘‘open’’ form
of the MeCP2 protein and facilitates its binding with DGCR8. Wepmental Cell 28, 547–560, March 10, 2014 ª2014 Elsevier Inc. 547
Figure 1. Upregulation of MaturemiRNAs in
the Hippocampus of mecp2 Null Mice and
the Role of MeCP2 in miRNA Processing
(A) Deep-sequencing data on the level of 720
mature miRNAs in hippocampal tissues from WT
and mecp2 null (KO) mice. A total of 314 showed
higher expression by R1.5-fold (red circles), and
63 showed %1.5-fold lower expression (blue cir-
cles) in KO mice, as compared to WT mice. The
rest showed differences in expression level <1.5-
fold (green circles). The pie chart depicts the per-
centage of three populations.
(B–D) Examination of primary, precursor, and
mature miR-134, miR-383, miR-382, and miR-
182 levels in MeCP2-shRNA-expressing neuron
lysates. Lentivirus-harboring MeCP2 RNAi was
seeded to mouse primary cortical neurons 2 DIV,
and RNA samples were collected 5 days after viral
infection. Primary, precursor, and mature miRNA
levels were analyzed with qPCR. ctrl, control
samples with GFP expression only.
(E) Examination of primary and precursor miR-134
levels in the presence of transcriptional blocker.
Procedures similar to those described in (B) were
used. Actinomycin D (1 mM) was applied for 3 hr
prior to RNA collection. Primary and precursor
miR-134 levels were analyzed with qPCR.
*p < 0.05 (t test). See also Figure S1 and Table S1.
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enriched miR-134 processing and thus regulates three of its
downstream target genes: cAMP-responsive element-binding
protein (CREB), LIM domain kinase 1 (LIMK1), and Pumilio2.
These results demonstrate the role for MeCP2 in participating
in nuclear miRNA processing directly and suggest a mechanism
for which dysregulation of MeCP2 levels leads to neurodevelop-
mental disorders.
RESULTS
Upregulation of miRNAs inmecp2 Null Mice
To determine whether the miRNA expression profile is altered
by MeCP2, we performed Solexa-based RNA sequencing
(RNA-seq) to assess global changes in the expression pattern
of miRNAs caused by the loss of MeCP2 inmecp2 null (knockout
[KO]) mice (Chen et al., 2001). Normalized with total reads, 314 of548 Developmental Cell 28, 547–560, March 10, 2014 ª2014 Elsevier Inc.all 720 (43.6%) sequenced miRNAs from
the hippocampus of mecp2 KO mice
were found to be significantly upregu-
lated for over 1.5-fold, as compared to
those found in the wild-type (WT) litter-
mates (Figure 1A; Table S1A available
online). In contrast, only 63 (8.7%) of
them were downregulated. To determine
whether overexpression of MeCP2 would
inhibit miRNA biogenesis, we applied
RNA-seq to mouse cortical neurons
with MeCP2 overexpressed by lentiviral-
based gene delivery. We found that
miRNAs are dramatically repressed: 243
of all 373 (65.1%) decreased expressionfor 1.5-fold with elevated MeCP2 protein level (Table S1B).
Among the upregulated miRNAs in mecp2 KO and downregu-
lated miRNAs in MeCP2 overexpression, there are 106 miRNAs
overlapped (Tables S1A and S1B). These data indicated that
MeCP2 significantly regulates miRNA biogenesis.
Among the upregulated miRNAs in the hippocampus of
mecp2 KO mice, we examined the level of 15 primary miRNA
transcripts that showed high expression in the CNS and found
that 12 of 15 showed no significant changes in the primary tran-
scripts (Figure S1A), suggesting that miRNA upregulation in
mecp2 KOmice is most likely caused by the loss of suppressive
action of MeCP2 on miRNA processing. To confirm the role of
MeCP2 in miRNA processing, we examined the primary, precur-
sor, and mature level of several candidate miRNAs repressed by
MeCP2, including miR-134, miR-383, miR-382, and miR-182.
We found that primary transcripts of these miRNAs are not
altered in neurons expressing either short hairpin RNA (shRNA)
Figure 2. The Direct Interaction between
MeCP2 and DGCR8
(A) Direct interaction betweenMeCP2 and DGCR8
shown by GST pull-down assay. The recombinant
GST and GST-DGCR8 purified from bacterial
sources were immobilized on glutathione beads,
combined with purified His-MeCP2, washed, and
analyzed on SDS-PAGE using antibodies indi-
cated. Target bands are indicated by asterisks.
WB, western blot.
(B) Interaction between various MeCP2 forms
and DGCR8 in HEK293 cells. HA-tagged WT or
mutated forms of MeCP2 were coexpressed with
myc-tagged DGCR8. Cell lysates were immuno-
precipitated with anti-HA antibody and analyzed
on SDS-PAGE. MeCP2DN, N terminus (aa 1–
91) deleted; MeCP2DMBD, methyl-DNA-binding
domain (aa 92–161) deleted; MeCP2DN+DMBD,
both N terminus and MBD (aa 1–161) deleted;
MeCP2380, C-terminal segment (aa 380–492)
deleted. IP, immunoprecipitation.
(C) Interaction between various DGCR8 forms and
MeCP2 in 293T cells. Myc-taggedWT, N segment,
or C segment of DGCR8 was coexpressed with
HA-tagged MeCP2. Cell lysates were immuno-
precipitated with anti-myc antibody and analyzed
on SDS-PAGE. DGCR8N, (aa 484–773) deleted;
DGCR8C, (aa 1–483) deleted.
(D) Direct interaction between MeCP2 and
DGCR8C shown by GST pull-down. Procedures
similar to those described in (A) were used.
(E) Direct interaction of MeCP2 with both RBD
domains of DGCR8. DGCR8DR12, (aa 511–685)
deleted; DGCR8DR2D, (aa 620–750) deleted.
(F) The role of RNA in the interaction of MeCP2 and
DGCR8. HA-MeCP2 and myc-DGCR8 were
cotransfected into 293T cells. RNase (final con-
centration of 0.25 mg/ml, 37C for 30min) was used
to digest RNA prior to immunoprecipitation. Cell
lysates were immunoprecipitated with IgG and
anti-HA antibody and analyzed on SDS-PAGE.
Lower panel shows quantitation of upper panel.
Error bars are SEM.
(G) Schematic illustration of interaction domains of
MeCP2 and DGCR8.
*p < 0.05 (t test). See also Figures S2 and S3.
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precursor and mature levels of these miRNAs are significantly
increased (Figures 1B–1D and S1B). We further examined the
primary, precursor, and mature levels of miR-134 in neurons
overexpressing MeCP2 and found that precursor and mature
forms of miR-134 were significantly downregulated by MeCP2
overexpression, but not primary miR-134 (Figure S1C), suggest-
ing that MeCP2 regulates the expression of these miRNAs
through a transcription-independent mechanism.
Furthermore, wemeasured the levels of primary and precursor
miR-134, one of MeCP2-repressed miRNAs, in the presence of
transcriptional blocker actinomycin D when MeCP2 was
knocked down by RNAi. We found that the upregulation of
miR-134 precursor by MeCP2 RNAi is not affected by actino-
mycin D treatment, further confirming that MeCP2 repressesDevelomiR-134 expression in a transcription-independent manner
(Figure 1E).
Direct Interaction of MeCP2 with DGCR8
To understand how MeCP2 regulates miRNA processing, we
performed glutathione S-transferase (GST) pull-down assays us-
ing bacteria-purified MeCP2 to examine the interaction between
MeCP2 and components of the nuclearmiRNA-processing com-
plex. We found that there was a direct interaction between
MeCP2 and DGCR8 (Figure 2A). Previous works showed that
the C terminus of MeCP2 may be critical for the interaction be-
tween MeCP2 and RNA-binding proteins (Buschdorf and Stra¨t-
ling, 2004; Young et al., 2005). Frame-shifting and truncated
mutations around amino acid 380, which led to a deletion of
100 aa from the C terminus, are frequently identified mutationspmental Cell 28, 547–560, March 10, 2014 ª2014 Elsevier Inc. 549
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deletions accounted for 15% of all genetic mutations identified
among the patients with RTT (Bebbington et al., 2010). We found
that in lysates of HEK293 cells, the binding of MeCP2380
(a MeCP2 mutant with deletion of residues 380–492) with coex-
pressed DGCR8 was significantly weaker than that of the WT
MeCP2 (Figure 2B). In contrast, binding with DGCR8 was not
affected for MeCP2DN, MeCP2DMBD, andMeCP2DN+DMBD, which
have the N terminus (aa 1–91), methyl-DNA-binding domain
(aa 92–161), and both domains deleted, respectively (Nan
et al., 1993; Figure 2B). The schematic illustration of domains
of MeCP2 and DGCR8 is shown Figures S2A and S2B. Thus,
the interaction of MeCP2 with DGCR8 depends on its C termi-
nus, but not the methyl-DNA-binding domain.
To characterize the direct interaction between MeCP2 and
DGCR8, we determined the binding affinity between DGCR8
and MeCP2 using Alpha Technology assay. Purified mouse
DGCR8C interacted with MeCP2DN+DMBD with an apparent Kd
value of 385 nM. This result further confirms the direct interaction
between DGCR8 and MeCP2 (Figures S3A and S3B).
Next, we examined whether MeCP2380 is still able to act as
a transcriptional repressor. We measured the mRNA level of
the BDNF gene, a well-known MeCP2 transcriptional target, in
mouse primary cortical neurons (Chen et al., 2003). We found
that BDNF mRNA is upregulated when MeCP2 is knocked
down by RNAi, consistent with previous findings, and both WT
MeCP2 and MeCP2380 are able to fully rescue BDNF mRNA to
a normal level, indicating that MeCP2380 retains its transcrip-
tional repressor activity (Figure S4A; Zhou et al., 2006). We
further examined the mRNA level of Acta2, a candidate gene
repressed by MeCP2, in mouse primary cortical neurons. We
found that Acta2 mRNA level was significantly downregulated
by expression of eitherWT or 380 truncated form ofMeCP2, indi-
cating that MeCP2380 is able to exhibit transcriptional repression
activity as WT MeCP2 (Figure S4B).
To further investigate which domain of DGCR8 is responsible
for binding to MeCP2, we generated N- and C-terminal halves of
DGCR8, consisting of residues 1–483 (DGCR8N) and 484–773
(DGCR8C), respectively (Figure S2B). Coimmunoprecipitation
(coIP) studies showed that the interaction with MeCP2 was
reduced for DGCR8N but not for DGCR8C, as compared to full-
length DGCR8 (Figure 2C). Furthermore, the GST pull-down
experiments with purified proteins showed that MeCP2 directly
binds to DGCR8C, but not DGCR8N (Figure 2D). Thus, a domain
responsible for the interaction with MeCP2 is located in
DGCR8C.
Because DGCR8C contains two RNA-binding domains and a
C-terminal tail that is required for Drosha binding (Yeom et al.,
2006), we prepared mutated forms of DGCR8 with deletions
in various domains: DGCR8DR12 deleted both RNA-binding
domains; and DGCR8DR2D, a mutated form, deleted RNA-bind-
ing domain 2 and theDrosha-bindingC-terminal tail (Figure S2B).
We found that DGCR8DR12 has no interaction with MeCP2, but
deletion of either one of the RNA-binding domains or Drosha-
binding domain had no effect (Figures 2E and S4C).
Because RNA-binding domains of DGCR8 are involved in
MeCP2 interaction, we also examined whether the presence of
RNA is critical for interaction of MeCP2 and DGCR8. We per-
formed an immunoprecipitation experiment with and without550 Developmental Cell 28, 547–560, March 10, 2014 ª2014 Elsevierribonuclease (RNase) treatment. Surprisingly, we found that
the interaction between MeCP2 and DGCR8 became much
stronger when RNAs were digested by RNase, suggesting that
MeCP2 may play a negative role in regulating the association
of DGCR8 with its RNA substrates (Figure 2F).
These results indicate that both RNA-binding domains of
DGCR8 are responsible for directly binding to MeCP2. Interac-
tion domains of MeCP2 and DGCR8 are illustrated in Figure 2G.
MeCP2 Competes with Drosha for Binding to DGCR8
and RNA
To explore the mechanism by which MeCP2 regulates nuclear
miRNA processing, we tested the possibility that the interaction
between MeCP2 and DGCR8 interferes with DGCR8 binding to
Drosha, which is the essential RNase III enzyme interacting
with the C terminus of DGCR8 in the miRNA-processing com-
plex (Yeom et al., 2006). First, we confirmed by coIP experiments
that, in HEK293 cells overexpressing full-length DGCR8,
DGCR8N, or DGCR8C, only DGCR8 and DGCR8C bind to endog-
enous Drosha (Figure 3A). Next, we tested the effect of MeCP2
on the binding of DRCR8 with Drosha. We coexpressed
DGCR8 with either full-length MeCP2 or MeCP2380 in HEK293
cells, and coIP results showed that the binding of DGCR8 with
Drosha was significantly weaker in the presence of the full-length
MeCP2, but not MeCP2380 (Figure 3B). We further confirmed this
finding by examining the interaction between DGCR8 and Dro-
sha in the presence of MeCP2 in a dose-dependent manner.
We coexpressed DGCR8 with an increasing amount of MeCP2
and found that the interaction between DGCR8 and Drosha
appeared to decrease when MeCP2 level increased (Figure 3C).
These results indicate that MeCP2 interaction with DGCR8 sup-
presses its binding with Drosha. The RNA-binding domains of
DGCR8 may be involved in MeCP2 binding, and the essential
Drosha-binding C-terminal tail is close to the RNA-binding do-
mains (Yeom et al., 2006). Therefore, the suppressive action of
MeCP2 may be caused by a direct competition with Drosha for
DGCR8 binding and/or a steric hindrance of MeCP2 on Drosha
binding with the DGCR8 C-terminal tail. Together, these results
strongly suggest that MeCP2 plays a role in interfering with
DGCR8-RNA association, as well as the DGCR8-Drosha interac-
tion, and thereby suppresses DGCR8/Drosha-mediated miRNA
processing.
Phosphorylation of MeCP2 at Ser80 Facilitates MeCP2
Binding with DGCR8
Phosphorylation of MeCP2 at Ser80 under resting status is
rapidly dephosphorylated upon neuronal activity (Tao et al.,
2009; Zhou et al., 2006). Through coIP experiments in HEK293
cells coexpressing DGCR8 and various forms of MeCP2, we
found that DGCR8bindingwithMeCP2was significantly lowered
whenSer80 ofMeCP2wasmutated to phosphorylation-deficient
alanine (MeCP2S80A) but elevated when it was mutated to phos-
phorylation-mimicking aspartate (MeCP2S80D, Figure 3D).
We reproduced a previous finding that MeCP2 is quickly de-
phosphorylated at the Ser80 site after depolarization (Figure 3E;
Tao et al., 2009). To investigate whether the interaction between
MeCP2 and DGCR8 may be regulated by neuronal activity, we
thus performed a coIP assay with endogenous proteins in pri-
mary culture neurons. We found that the interaction of MeCP2Inc.
Figure 3. MeCP2 Interrupts the Interaction between DGCR8 and Drosha, Depending on Phosphorylation of Ser80
(A) Drosha binds to the C terminus of DGCR8. Myc-tagged WT, N segment, or C segment of DGCR8 was expressed in 293T cells. Cell lysates were immu-
noprecipitated with anti-myc antibody and analyzed on SDS-PAGE with Drosha western blotting.
(B) The interaction between Drosha and DGCR8 with the presence of WT MeCP2 and MeCP2380. Myc-tagged DGCR8 was coexpressed with HA-tagged
WT MeCP2 or MeCP2380, respectively. Cell lysates were immunoprecipitated with anti-myc antibody and analyzed on SDS-PAGE. Lower panel shows quan-
tification of (B).
(C) The interaction between Drosha and DGCR8 with the different amounts of MeCP2 protein. Different amounts of HA-tagged WT MeCP2 were coexpressed
with myc-tagged DGCR8 as indicated. Cell lysates were immunoprecipitated with anti-myc antibody and analyzed on SDS-PAGE. Right panel shows
quantification of (C).
(D) Phosphorylation of MeCP2 Ser80 is critical for binding with DGCR8. HA-tagged WT MeCP2, MeCP2S80A, or MeCP2S80D was coexpressed with myc-tagged
DGCR8. Cell lysates were immunoprecipitated with anti-myc antibody and analyzed on SDS-PAGE with HA antibody. Lower panel shows quantification of (D).
(E) Western blot of MeCP2 Ser80 upon depolarization. Mouse primary cortical neurons were cultured 5–7 DIV and applied with the stimulus indicated. Samples
were collected and analyzed with the antibodies indicated.
(F) Immunoprecipitation of endogenous MeCP2 and DGCR8 from lysates of mouse cultured cortical neurons. Mouse primary cortical neurons were cultured at 5
DIV and stimulated by 50 mMKCl for 30 min and immunoprecipitated with anti-MeCP2 antibody; samples were washed and analyzed on SDS-PAGE by western
blot with the antibodies indicated. Lower panel shows quantification of (F).
(G) Interaction between Drosha and DGCR8 in neurons depleting MeCP2. Mouse primary cortical neurons were seeded with either GFP or MeCP2-shRNA-
expressing lentivirus at 2 DIV and collected for coIP experiments at 7 DIV. Cell lysates were immunoprecipitated with either IgG or anti-Drosha antibodies and
analyzed by SDS-PAGE with antibodies indicated. Lower panel shows quantification of (G).
(H) Interaction between Drosha and DGCR8 in brain lysates of mecp2 TG mice. Hippocampal lysates were collected from mecp2 TG and WT littermates and
immunoprecipitated with either IgG or anti-Drosha antibodies and analyzed by SDS-PAGEwith the antibodies indicated. Lower panel shows quantification of (H).
Error bars are SEM. *p < 0.05 (t test).
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decreased significantly after depolarization (Figure 3F).
Next, we investigated whether the interaction of DGCR8 with
Drosha would be affected by MeCP2 in neurons. After knocking
down MeCP2 by RNAi, we found that the interaction between
DGCR8 and Drosha dramatically increased in mouse corticalDeveloculture neurons (Figure 3G). Consistently, interaction between
DGCR8 and Drosha appeared to significantly decrease in
a mecp2 transgenic (TG) mice model where mecp2 was
strongly overexpressed genetically, compared to WT littermates
(Figure 3H; Collins et al., 2004). Thus, this evidence strongly
suggests that MeCP2 interferes with the assembly of thepmental Cell 28, 547–560, March 10, 2014 ª2014 Elsevier Inc. 551
(legend on next page)
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miRNA processing in vivo.
Intramolecular Interaction of MeCP2 Protein Regulated
by the Phosphorylation Status of Ser80
However, as we showed, the N-terminal region of MeCP2 is not
required for binding with DGCR8. To address how phosphoryla-
tion of Ser80 contributes to the interaction between MeCP2
and DGCR8, we used fluorescence resonance energy transfer
(FRET)-based analysis to examine whether phosphorylation of
Ser80 would alter the conformation of MeCP2, instead of directly
interacting with DGCR8 (Hillebrand et al., 2007). We tagged two
distinct fluorescent proteins, cyan fluorescent protein (CFP) and
yellow fluorescent protein (YFP), onto the N and C terminus of
MeCP2, respectively. The CFP-MeCP2-YFP probe expressed
strictly in the nucleus of both 293T cells and mouse primary
cortical neurons, as shown by our immunostaining results (Fig-
ure S4D). We found that the FRET signals increased when
the Ser80 was mutated to phosphorylation-deficient alanine,
compared to WT and the MeCP2S80D mutant, because Ser80
of WT MeCP2 is phosphorylated in basal condition in 293T cells
(Figures 4B and S4E). These data suggest that there may be in-
tramolecular interactions between the N- and C-terminal halves
of unphosphorylated MeCP2, which restrict the accessibility of
MeCP2 by DGCR8, and that phosphorylation of Ser80 of
MeCP2 opens up the conformation and facilitates its binding
to DGCR8, as schematically shown in Figure 4E. We further
performed the FRET experiments with the CFP-MeCP2-YFP
probe in neurons with and without depolarization stimulus. We
found that FRET efficiency of the CFP-MeCP2-YFP probe was
increased upon potassium chloride (KCl) stimulus (Figure 4B),
supporting that there is a conformational change in MeCP2
protein upon neuronal activity.
To examine this potential intramolecular interaction further,
we performed a GST pull-down assay using bacterially purified
GST-tagged N (residues 1–305) and His6-tagged C (residues
306–492) terminal halves of MeCP2. We found that there was a
direct interaction between GST-MeCP2-N and His-MeCP2-C
(Figure 4C). Furthermore, we examined the role of Ser80 phos-
phorylation in the interaction between MeCP2-N and MeCP2-C
using a coIP assay in 293T cells. We found that phosphoryla-
tion-deficient MeCP2-N-S80A binds to MeCP2-C in a much
stronger fashion, compared to phosphorylation-mimicking
MeCP2-N-S80D (Figure 4D). These data indicate that, in theFigure 4. Intramolecular Interactions in MeCP2 Protein Regulated by P
(A) FRET efficiency is increased in S80A mutant compared with the WT MeCP2 a
MeCP2S80A, and MeCP2S80D. Fluorescence dot signals from ten cells of each co
(B) FRET efficiency is increased in MeCP2 FRET probe upon depolarization in n
transfected into mouse primary cortical neurons. Under depolarization conditions
ten cells of each condition were collected and measured. p = 0.023 (Kolmogoro
(C) Direct interaction between GST-MeCP2-N (aa 1–305) and His-MeCP2-C (aa
MeCP2-N purified from bacterial sources were immobilized on glutathione beads
(D) The interaction betweenMeCP2-N andMeCP2-C regulated by phosphorylatio
myc-MeCP2-C. Cell lysates were immunoprecipitated with anti-HA antibody and
SEM. *p < 0.05 (t test).
(E) In the unphosphorylated state (or the S80A mutant), the accessibility of the
interaction, between the MeCP2 CTD and the MeCP2 N-terminal region includin
rupting this intramolecular inhibition of MeCP2 and forming an open conformatio
See also Figure S4.
DeveloSer80 unphosphorylated state, MeCP2 forms an intramolecular
interaction between its N- and C-terminal halves, which makes
the C-terminal half inaccessible for binding to DGCR8.
Taken together, we propose that phosphorylated MeCP2
binds to DGCR8 under resting status in neurons. When neuronal
calcium signaling is activated, dephosphorylation of MeCP2
Ser80 leads to its release from DGCR8 and allows activity-
dependent miRNA processing to take place (Figure 4E).
MeCP2 Regulates CREB, LIMK1, and Pumilio2 Protein
Levels via Suppressing miR-134
To further determine the role of phosphorylation of MeCP2 Ser80
in miRNA processing, we focused on the miR-134, a critical
miRNA for neural development (Schratt et al., 2006; Gao et al.,
2010). We measured primary, precursor, and mature forms
of miR-134 under different manipulations of MeCP2. First, we
found that the precursor and mature forms of miR-134, but not
primary transcript, were significantly decreased in neurons ex-
pressing WT MeCP2, whereas overexpression of the truncated
form MeCP2380 has no effects on miR-134 levels (Figure 5A).
Consistently, we found that overexpression of phosphoryla-
tion-mimicking MeCP2S80D significantly decreased precursor
and mature miR-134, but MeCP2S80A has no effect (Figures 5B
and 5C). Thus, both our loss- and gain-of-function data indicate
that phosphorylation of MeCP2 Ser80 is required for repressing
miR-134 processing.
To investigate the functional consequences of MeCP2 regula-
tion of miR-134 processing, we further examined whether the
level of targeted proteins of MeCP2-suppressed miR-134 is
altered in the absence of MeCP2. It was reported that miR-134
targets three critical regulators for neural development and plas-
ticity: CREB, LIMK1, and Pumilio2 (Fiore et al., 2009; Gao et al.,
2010; Schratt et al., 2006). We found that overexpression of
MeCP2 in mouse primary cortical neurons indeed leads to an
increase of CREB level (Figure 5D). Interestingly, when we coex-
pressed DGCR8 along withMeCP2 in cortical neurons, we found
that the introduction of DGCR8 could neutralize the effect of
MeCP2 overexpression and rescue the CREB to the normal level
(Figure 5D), suggesting that MeCP2-induced CREB upregulation
depends on interaction of MeCP2 and DGCR8. Consistently, we
found that the level of mature miR-134 was indeed repressed by
MeCP2 overexpression and rescued by coexpression of DGCR8
(Figure 5E). Furthermore, we found that the expression of the
MeCP2380-truncated form was not able to increase CREB levelhosphorylation of Ser80
nd MeCP2S80D. CFP and YFP are tagged onto N and C termini of WT MeCP2,
ndition were collected and measured. p < 0.001 (Kolmogorov-Smirnov test).
eurons. CFP and YFP are tagged onto N and C termini of WT MeCP2 and are
, neurons were stimulated with 50 mM KCl for 3 hr. Fluorescence signals from
v-Smirnov test).
306–492) shown by GST pull-down assay. The recombinant GST and GST-
, combined with purified His-MeCP2-C, washed, and analyzed on SDS-PAGE.
n of Ser80. HA-MeCP2-N-S80A or HA-MeCP2-N-S80D was coexpressed with
analyzed on SDS-PAGE. Lower panel shows quantification of (D). Error bars are
MeCP2 C-terminal domain (CTD) is restricted by a potential intramolecular
g S80. Phosphorylation of S80 increases the CTD accessibility, likely by dis-
n.
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Figure 5. Regulation of CREB, LIMK1, and Pumilio2 Expression by MeCP2 via Suppressing miR-134
(A) Examination of primary, precursor, and mature miR-134 levels in WT and MeCP2380 mutation forms of MeCP2-expressing neuron lysates. Lentivirus-
harboring WT and 380 truncated forms of MeCP2 were seeded to mouse primary cortical neurons 2 DIV, and RNA samples were collected 5 days after viral
infection. Primary, precursor, and mature miR-134 levels were analyzed with qPCR.
(B and C) Examination of primary, precursor, and mature miR-134 levels in WT, S80A, and S80D mutation forms of MeCP2-expressing neuron lysates. The
experimental procedure is the same as that in (A).
(D and E) Effect of DGCR8 onMeCP2-regulated levels of miR-134 andCREB.MeCP2- and DGCR8-expressing plasmids were electroporated intomouse primary
cortical neurons as indicated. RNA and protein samples were collected 5 days after electroporation. CREB levels were analyzed with western blots. Lower panel
shows quantification of (D). (E) miR-134 levels were analyzed with qPCR.
(F) Regulation of CREB level by WT and MeCP2380 mutant. Mouse E15 cortical neurons were dissociated and electroporated with GFP, WT, and 380 truncated
forms of MeCP2. Cells were lysated at 5–6 DIV and analyzed on SDS-PAGE.
(G) Regulation of CREB and LIMK1 protein level by MeCP2 overexpression. Mouse E15 cortical neurons were dissociated and electroporated with GFP, WT, and
S80A mutant forms of MeCP2. Cells were lysated at 5–6 DIV and analyzed on SDS-PAGE.
(H) WT, but not S80A, MeCP2 is able to rescue CREB and LIMK1 protein levels after MeCP2 knockdown. Mouse E15 cortical neurons were dissociated and
seeded with lentivirus-harboring shRNA or with shRNA-resistant rescue from WT or S80A form of MeCP2 for 5 days.
(I) miR-134 is required for MeCP2-regulated CREB and LIMK1 expression. Mouse cortical neurons were dissociated and electroporated with miRNA inhibitor
control or miR134 inhibitor. Lentivirus-harboring GFP and shRNA against MeCP2 were seed at 2 DIV. Neurons were lysated at 7 DIV and analyzed on SDS-PAGE.
(J) Bidirectional regulation of miR-134 in mecp2 KO and TG mice. RNAs were collected from hippocampal lysates of mecp2 KO, TG mice along with their WT
littermates. Levels of mature miR-134 were analyzed by qPCR. Error bars are SEM. *p < 0.05 (t test).
(K) Bidirectional regulation of CREB and LIMK1 protein levels in mecp2 KO and TG mice. Left panel shows that CREB and LIMK1 protein levels decreased in
hippocampus ofmecp2 KOmice. Hippocampal samples were collected from 2-week-oldmecp2 KOmice andWT littermates. Right panel shows that CREB and
LIMK1 protein levels were elevated in hippocampus ofmecp2 TG mice. Hippocampal samples were collected from 2-week-old mecp2 TG and WT littermates.
(L) Bidirectional regulation of Pumilio2 protein levels inmecp2 KO and TG mice. Left panel shows that Pum2 protein levels decreased in hippocampus ofmecp2
KOmice. Hippocampal samples were collected from 2-week-old WT and KOmice. Right panel shows that Pum2 protein levels were elevated in hippocampus of
mecp2 TG mice. Hippocampal samples were collected from 2-week-old WT and mecp2 TG mice.
See also Figures S5 and S6.
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MeCP2 Suppresses Nuclear MicroRNA Processingin cortical neurons as WT MeCP2 (Figure 5F). These data indi-
cate that the interaction with DGCR8 is critical for MeCP2 to
posttranscriptionally regulate CREB level.554 Developmental Cell 28, 547–560, March 10, 2014 ª2014 ElsevierWe found that the CREB and LIMK1 protein levels were signif-
icantly elevated when the WT MeCP2, but not MeCP2S80A, was
overexpressed in cultured neurons, consistent with our findingInc.
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MeCP2 Suppresses Nuclear MicroRNA Processingthat MeCP2S80A showed much weaker interaction with DGCR8
than WT MeCP2 (Figure 5G). Next, we found that the expression
of WT MeCP2 with same-sense mutations of shRNA-targeting
sites in these neurons rescued the reduction of CREB and
LIMK1 caused byMeCP2RNAi, whereas the expression ofMeC-
P2S80A also containing same-sense mutations had no effect on
CREB and LIMK1 protein levels (Figure 5H). These data indicate
that the phosphorylation of the MeCP2 S80 site is essential for
upregulation of CREB level by MeCP2 overexpression, further
suggesting that interfering with miRNA processing by MeCP2
could lead to multiple physiological consequences by affecting
target gene expression.
Importantly, we found that the protein levels of CREB and
LIMK1 were also decreased by downregulating MeCP2 with
expression of specific shRNA in cultured cortical neurons, which
was largely blocked by introducing the miR-134 inhibitor that
was complementary to the mature miR-134 (Figure 5I), strongly
suggesting that miR-134 is required for MeCP2 regulating
CREB and LIMK1 protein levels. Notably, the levels of primary
miR-134 transcripts, CREB, and LIMK1 remain constant under
these manipulations, indicating that the regulation by MeCP2
on these components occurs at the posttranscriptional level
(Figures S5A–S5F).
We also examined the protein level of Pumilio2 under different
manipulations of MeCP2. Consistently, we found that Pumilio2
protein level decreases in MeCP2 RNAi and increases in
MeCP2 overexpression samples (Figure S5G). The mRNA levels
of Pumilio2 are not altered in either MeCP2 RNAi or overexpres-
sion conditions, compared to control (Figure S5H).
To determine whether miR-134 and its target proteins would
be regulated in vivo, we examined levels of mature miR-134,
CREB, LIMK1, and Pumillio2 proteins in hippocampal lysates
of MeCP2 KO and TG mice, using WT littermates as control
(Chen et al., 2001; Collins et al., 2004). First, we found that the
mature miR-134 level significantly increased in brain lysates
of mecp2 KO, whereas it decreased in those of mecp2 TG,
compared to WT mice (Figure 5J). Next, we found that the level
of CREB and LIMK1 dramatically decreased in the hippocampus
of mecp2 KO mice as compared to WT (left panel of Figure 5K).
On the other hand, we found that CREB and LIMK1 protein levels
notably increased in mecp2 TG mice (right panel of Figure 5K).
This is consistent with the previous finding that the protein level
of CREB was increased in the hypothalamus of mecp2 TG mice
compared to WT mice (Chahrour et al., 2008). Importantly,
mRNA levels of primary miR-134, CREB, and LIMK1 were not
affected in either mecp2 KO or TG mice (Figures S6A–S6F).
We also found that the protein level of Pumilio2 decreased in
the hippocampus ofmecp2 KO and increased in the hippocam-
pus ofmecp2 TG mouse (Figure 5L). Taken together, these data
indicate that MeCP2 posttranscriptionally controls levels of miR-
134, CREB, LIMK, and Pumilio2 protein in vivo.
Repression of Dendritic Growth by MeCP2 via
Controlling miRNA Processing
Next, we would like to address how the interaction of MeCP2
with DGCR8 contributes to neural development. The duplica-
tions of MECP2-containing loci lead to severe autism spectrum
disorders in human, suggesting that gain-of-function mutations
ofMECP2may cause destructive consequences to the develop-Develoment of the nervous system (Ramocki et al., 2009). Consistently,
it was reported that dendritic growth of hippocampal neurons is
inhibited when MeCP2 is elevated and TG mouse with mecp2
overexpression appears to have phenotypes mimicking the
MECP2 duplication disorders (Zhou et al., 2006). Furthermore,
CREB, LIMK1, and Pumilio2, these target genes of MeCP2
shown above, were reported to play critical roles in regulating
dendritic growth (Redmond et al., 2002; Schratt et al., 2006;
Vessey et al., 2010).
We would like to address whether this inhibition of dendritic
growth byMeCP2 is due to the repression ofmiR-134.We exam-
ined the dendritic growth of the mouse primary cortical cul-
ture neurons and found that expression of WT MeCP2, not
MeCP2S80A andMeCP2380, leads to strong inhibition of dendritic
growth (Figures 6A and 6B). We coexpressed miR-134 and its
antisense control along with WT MeCP2 in cultured neurons.
Strikingly, we found that expression of miR-134 was able to fully
rescue the dendritic growth defects caused by WT MeCP2
overexpression, but miR-134 antisense control had no effect
(Figures 6A and 6B). We expressed miR-134 and the MeCP2
RNAi construct alone in the cortical neurons and found that there
were no significant changes in dendritic growth (Figures S7A–
S7D). These data indicate that MeCP2 represses neuronal den-
dritic growth by suppressing miR-134.
Next, we asked whether the calcium-dependent dephosphor-
ylation of MeCP2 Ser80may contribute to the well-characterized
activity-dependent dendritic growth process in neurons (Red-
mond et al., 2002). We transfected WT MeCP2 and MeCP2S80D
mutation into mouse primary cortical neurons and depolarized
the neuron with KCl. We found that the activity-dependent den-
dritic growth was completely abolished only when the S80D
mutated form of MeCP2 was introduced, indicating that cal-
cium-dependent dephosphorylation of MeCP2 Ser80 is required
for activity-dependent dendritic outgrowth (Figures 6C and 6D).
Finally, we examined the role ofMeCP2 in dendritic growth and
spine development in hippocampal slice culture preparations.
We used gene gun-based DNA delivery on rat postnatal day 7
(P7) hippocampal slice cultures and found that introduction
of WT MeCP2 significantly decreased dendritic growth, as
measured by total dendritic length (Figures 7A and 7B). However,
overexpression of two mutant forms of MeCP2, MeCP2S80A and
MeCP2380, had no such effect (Figures 7A and 7B). Note that
MeCP2S80A and MeCP2380 are not able to bind to DGCR8 and
repress miRNA processing. Furthermore, we measured spine
density in the above preparations and found that overexpression
of WT MeCP2, but not MeCP2S80A and MeCP2380, strongly
repressed spine density in hippocampal slice culture, further
suggesting that the role of MeCP2 on spine development also
requires the interaction of MeCP2 and DGCR8 (Figures 7C
and 7D; Han et al., 2013; Schratt et al., 2006). Taken together,
these results indicate that the gain of function of MeCP2 leads
to inhibition of dendritic and spine growth, depending on the
repression of DGCR8/Drosha-dependent miR-134 processing
by MeCP2.
DISCUSSION
In this study, we have identified a mechanism by which MeCP2
regulates gene expression by suppressing nuclear miRNApmental Cell 28, 547–560, March 10, 2014 ª2014 Elsevier Inc. 555
Figure 6. MeCP2 Regulates Dendritic Growth by Inhibiting miR-134, and Dephosphorylation of MeCP2 S80 Is Required for Activity-Depen-
dent Dendritic Growth
(A) Example picture of mouse primary cortical neurons transfected at 3 DIV with GFP alone and GFP with constructs indicated. Neurons were fixed and
immunostained with GFP antibody at 6 DIV for measurement of dendritic length.
(B) Measurements of total dendritic length of each condition. *p < 0.01 (t test).
(C) Example picture of mouse primary cortical neurons with each construct transfected. Constructs expressing MeCP2 WT and mutations were transfected into
cortical neuron 2 DIV and stimulated by KCl 48 hr after transfection. KCl with a final concentration of 25mMwas given to mouse primary cortical neurons for 36 hr
before neurons were fixed and performed following experiments. Immunostaining with GFP antibody was used to examine the dendritic growth.
(D) Measurements of total dendritic length of each condition. *p < 0.01 (t test). A total 12–15 neurons from each condition were randomly selected andmeasured.
See also Figure S7.
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MeCP2 Suppresses Nuclear MicroRNA Processingprocessing through direct interaction with DGCR8, a key compo-
nent of theprocessingcomplex. Thismechanismcould contribute
significantly to theMeCP2’s regulationof proteins that play impor-
tant neuronal functions, e.g., CREB, LIMK1, and Pumilio2.
Here, we showed that as a nuclear protein, MeCP2 could not
only repress gene transcription by binding to methylated DNA556 Developmental Cell 28, 547–560, March 10, 2014 ª2014 Elsevierand recruiting transcriptional repressors (Nan et al., 1998) but
also suppress miRNA processing by binding to RNA-binding
domains of DGCR8. Whether MeCP2 may interact with other
RNA-binding proteins and participate in RNA biogenesis and
metabolism needs to be further investigated. The previous study
that MeCP2 interacts with the RNA-splicing complex suggestsInc.
Figure 7. MeCP2 Inhibits Dendritic Growth and Spine Formation in Hippocampal Slice Cultures
(A) Typical pictures of rat hippocampal slice culture neurons. Hippocampal slices from P7 rat were transfected at 3 DIV with GFP alone and GFP with MeCP2,
MeCP2S80A, and MeCP2380 by gene gun delivery. Slices were fixed and immunostained with GFP antibody at 9 DIV.
(B) Measurements of total dendritic length of each condition. *p < 0.01 (t test). For each condition, 18 neurons were randomly selected and measured. At least
900 mm dendrites were analyzed for each condition.
(C) Typical pictures of spines of rat hippocampal slice culture neurons. Experimental procedures are the same as (A).
(D) Measurements of spine density over 10 mm dendrites of each condition. *p < 0.01 (t test).
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MeCP2 Suppresses Nuclear MicroRNA Processingthat MeCP2 may be widely involved in RNA metabolism pro-
cesses (Young et al., 2005).
How miRNA biogenesis in neurons is regulated by neuronal
activity is an important question. A previous report showed
that light-induced neuronal activity is critical for fast turnover
of mature miRNAs in retina cells (Krol et al., 2010). Our study
suggests that miRNA biogenesis may be positively regulated
by neural activity, as controlled by calcium-dependent dephos-
phorylation of MeCP2 and derepressing of miRNA processing.
Thus, this work may represent regulation over different levels
or in different tissues.We suggest thatMeCP2-regulated nuclear
miRNA processing plays a critical role for miRNA biogenesis in
cortical and hippocampal neurons.
It is important that nuclear miRNA processing is critical for
proper synaptic function as shown by Ullian and colleagues
that deletion of DGCR8 leads to defects of inhibitory synap-
tic transmission (Hsu et al., 2012). Whether MeCP2 may
be involved in inhibitory synaptic transmission via controllingDevelonuclear miRNA processing would be an interesting question
to address.
An important issue regarding the pathophysiology of MeCP2-
related disorders is that both loss and gain of functions of
MeCP2 lead to severe pathological symptoms. Loss-of-function
mutations of MECP2 lead to RTT, whereas duplication of
MECP2-containing locus leads to autism spectrum disorders.
It is difficult to provide a satisfactory explanation for why a higher
level of this protein leads to diseases, if solely considering the
transcriptional regulation point of view. Our study showed that
MeCP2 could regulate expression levels of target genes by
fine-tuning the level of miRNAs, as shown for CREB, LIMK1,
and Pumilio2 protein levels. Thus, this mechanism provides an
alternative explanation for the dose effect of MeCP2 in neural
development. As we showed in the Results, increasing the
amount of MeCP2 protein leads to repression of mature miR-
134, which then causes various dysregulation of protein targets
as well as cellular consequences.pmental Cell 28, 547–560, March 10, 2014 ª2014 Elsevier Inc. 557
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MeCP2 Suppresses Nuclear MicroRNA ProcessingNuclear miRNA processing is a highly regulated process, as
exemplified by the effects of p53 and SMAD proteins that are
involved in tumorigenesis (Davis et al., 2008; Suzuki et al.,
2009). Our finding of a posttranscriptional function of MeCP2
in regulating miRNA maturation suggests that intervening dysre-
gulated miRNA processing represents a potential therapeutic
approach in the treatment of RTT.
EXPERIMENTAL PROCEDURES
Plasmids
The rat MeCP2-e2 gene was a gift of Dr. Adrian Bird. Other constructs of
MeCP2 mutations and truncations were all generated based on this construct.
In brief, MeCP2S80D,MeCP2DMBD,MeCP2S80A, andMeCP2380 were generated
usingKOD-Plus (Toyobo) according tomanufacturer’s instructions. Themouse
MeCP2 shRNA was directed against the sequence as follows: 50-AAGTCA
GAAGACCAGGATC-30. MeCP2 siRNAs (Thermo Scientific, against mouse
MeCP2, on-target plus SMART pool L-044034-09-12, 50-CCUGAAGGUUGG
ACACGAA-30, 50-UGACAAAGCUUCCCGAUUA-30, 50-CCGAAUUGCUGCUG
CUUUA-30, and 50-CGAAAUGGCUGUGUAGCAA-30), along with scrambled
siRNA as control. miR-134 sequence was amplified with primers as the
following: forward, 50-cagtgaattcccaaccttggtgaggcagctg-30; and reverse,
50-cagtgaattctcctggtccactgagcaggc-30. The miR-134 sequence or reverse
and complement sequence was inserted into FUGW to get miR-134
plasmid/miR-134rev plasmid. mmu-miR-134 inhibitor was purchased from
GenePharma.com. Inhibitors are 2-methylated-modifiedRNAoligo completely
complementary to mmu-miR-134 and purified by high-performance liquid
chromatography prior to being used. miR-134 inhibitors were introduced into
neurons by Amaxa Nucleofector at the time of seeding. The mouse DGCR8
cDNA was amplified from total cDNA of mouse cortical neurons. DGCR8 trun-
cations were generated as described previously by Yeom et al. (2006).
Antibodies
Antibodies used in this study were as follows: MeCP2 (#3456, Cell Signaling
Technology; MP4591, MP4601, ECM Biosciences); Drosha (#3364; Cell
Signaling Technology); DGCR8 (sc-48473; Santa Cruz Biotechnology); Myc
epitope tag (#M20002; Abmart); HA epitope tag (#M20013; Abmart); GST
(#2622; Cell Signaling Technology); CREB (#9197; Cell Signaling Technology);
LIMK1 (#3842; Cell Signaling Technology); and GAPDH (ab8245; Abcam).
Cell Culture
Embryonic day 15 (E15)–E16 mouse cortical cells were cultured and trans-
fected with Amaxa Nucleofector in 6-well plates. Cells were collected at
5–7 days in vitro (DIV) for further analysis. Lentivirus used in this study was
made with 108109 viral genome/ml by the Obio Technology (Shanghai) and
the Neuronbiotech.
Genetic-Modified Mice
mecp2 TG mice (008679) and nestin-cre mice (003771) were purchased from
Jackson Laboratory; mecp2 null (000415) and loxP-floxed mecp2 (011918)
were purchased from Mutant Mouse Regional Resource Center at University
of California Davis. The use and care of animals complied with the guideline
of the Animal Advisory Committee at the Shanghai Institutes for Biological
Science, CAS.
Quantitative Real-Time PCR Assays
For quantitative real-time PCR assays, total RNA was extracted from mouse
cortical neurons usingmirVanamiRNA Isolation Kit (Ambion). For themeasure-
ment of primary miRNA transcripts, the large-sized RNA fractions (>200 bp)
were used for reverse transcription. cDNAwas synthesized by poly-dT primers
from 1 mg of purified RNA (>200 bp fraction) by iScript cDNA Synthesis Kit
(Bio-Rad). SYBR Premix Ex Taq from Takara was used in this study. Quantita-
tive real-time PCR was performed with the Rotor-Gene Q machine (QIAGEN).
Results were normalized to GAPDH, and data analysis was done by using the
comparative CT method in software by QIAGEN.
For the measurement of precursor and mature miRNA levels, small fraction
RNAs (<200 bp) were isolated with mirVana miRNA Isolation Kit. Mature558 Developmental Cell 28, 547–560, March 10, 2014 ª2014 ElseviermiRNAs were detected and quantified with Hairpin-it miRNAs qPCR Quantifi-
cation Kit (GenePharma). For the measurement of precursor miRNAs, small
RNA fraction was reverse transcribed with miScript II RT Kit (QIAGEN) and
quantified with quantitative real-time PCR assays using precursor-specific
primers from QIAGEN.
Primers used in quantitative real-time PCR assays were as follows:
miR-134 forward, 50-GGGTGTGTGACTGGTTGACCA-30
miR-134 reverse, 50-GGGTTGGTGACTAGGTGGCC-30
CREB forward, 50-TCAGCCGGGTACTACCATTC-30
CREB reverse, 50-TTCAGCAGGCTGTGTAGGAA-30
LIMK1 forward, 50-ATGAGGTTGACGCTACTTTGTTG-30
LIMK1 reverse, 50-CTACACTCGCAGCACCTGAA-30
miR-383 forward, 50-CTCCTCAGATCAGAAGGTGACTG-30
miR-383 reverse, 50-CTCTTTCTGACCAGGCAGTG-30
miR-382 forward, 50-TTGAAGAGAAGTTGTTCGTGGTG-30
miR-382 reverse, 50-GTGTTGTCCGTGAATGATTCGT-30
miR-182 forward, 50-CCATTTTTGGCAATGGTAGAAC-30
miR-182 reverse, 50-CATAGTTGGCAAGTCTAGAACC-30
miR-137 forward, 50-ACTCTCTTCGGTGACGGGTA-30
miR-137 reverse, 50-CGCTGGTACTCTCCTCGACT-30
miR-132 forward, 50-ACCGTGGCTTTCGATTGTTA-30
miR-132 reverse, 50-GGCGACCATGGCTGTAGACT-30
miR-128 forward, 50-ATTGGCCTTCTTCCTGAGC-30
miR-128 reverse, 50-TCAGGAAGCAGCTGAAAAAG-30
miR-7a forward, 50-TGGATGTTGGCCTAGTTCTG-30
miR-7a reverse, 50-TGGCAGACTGTGATTTGTTG-30
let-7i forward, 50-CCCTGGCTGAGGTAGTAGTTTG-30
let-7i reverse, 50-ATCACCAGCACTAGCAAGGC-30
miR-27b forward, 50-TGCAGAGCTTAGCTGATTGG-30
miR-27b reverse, 50-CCTTCTCTTCAGGTGCAGAAC-30
miR-27a forward, 50-GAGGAGCAGGGCTTAGCTG-30
miR-27a reverse, 50-CAGGGGGCGGAACTTAGC-30
miR-124-1 forward, 50-TGTTCACAGCGGACCTTGA-30
miR-124-1 reverse, 50-GAAGCCTGCTACCCGTACT-30
miR-124-2 forward, 50-TGCAATGAGTCACTTGCTTC-30
miR-124-2 reverse,: 50- CCCTTCCTAACTTCTCTCGG-30
miR-124-3 forward, 50-AGCGGACCTTGATTTAATGTC-30
miR-124-3 reverse, 50-GGGCCATTTCCATGAGAAAG-30
miR-153 forward, 50-CGGTGTCATTTTTGTGACGT-30
miR-153 reverse, 50-CAATGATCACTTTTGTGACTATGC-30
miR-135a forward, 50-AAGTGACTCACCTCTGCCAG-30
miR-135a reverse, 50-TGCCAGCATTTCAGTGTGTG-30
miR-340 forward, 50-CTTGGTGTGATTATAAAGCAATGA-30
miR-340 reverse, 50-CCAGGTATGGCTATAAAGTAACTGA-30
BDNF forward, 50-TGCCTAGATCAAATGGAGCTTCTC-30
BDNF reverse, 50-CCGATATGTACTCCTGTTCTTCAGC-30
PUM2, forward 50-TCCTCATCCAGTTTGCATTTAG-30
PUM2, reverse 50-TCAGATCTATTATAGCGGAGCC-30.
GST Pull-Down Assay
GST pull-down assay was performed as described before (Qiu and Ghosh,
2008). Overnight express TB medium from Novagen (catalog #71491-4) was
used to generate recombinant protein from E. coli.
Immunoprecipitation
For coIP in 293T cells, HEK293T cells were cultured on 6-well plates, and
transfection was performed when the cells reached 50% confluence. FuGENE
HD (Roche, Promega) was used for transfection. A total of 5 mg of DNA was
used per well in 6-well plates at a molar ratio of 1:1 for myc-tagged and
HA-tagged constructs. Cells were harvested 24 hr after transfection. The cells
were rinsed with ice-cold PBS, harvested, and lysed for 20 min at 4C in a
modified RIPA buffer. Of the supernatant, 5% was saved for the input control,
and the rest was incubated with 2 mg anti-HA agarose beads (Abmart) or anti-
myc agarose beads overnight at 4C. The immune complex was washed three
times with the lysis buffer, then boiled in 13 SDS loading buffer with 20 mM
DTT, and resolved by the 10% SDS-PAGE. The gel was transferred to polyvi-
nylidene fluoride membranes (Amersham), and the membrane was blocked
with 5% milk in Tris-buffered saline and Tween 20 (TBST) buffer for 1 hr. ItInc.
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times in TBST, and the signals were revealed by horseradish peroxidase
reaction using the SuperSignal Chemiluminescent Substrate (Pierce).
RNA-Seq Deep Sequencing
Hippocampus RNA samples were prepared from P30 WT and KO mice and
were sequenced and analyzed by Solexa of BGI Shenzhen. RNA-seq sample
preparation and data analysis were performed as described by Kwak et al.
(2009). RNA from cultured mouse cortical neurons with MeCP2 manipulations
and depolarization stimulus were collected 5–7 DIV and sequenced by Solexa
GAII of Shanghai Bio-Chip. Standard Solexa TruSeq-Small RNA sequence
protocol was used. The technical method is described in the TruSeq Small
RNA Sample preparation guide on the Illumina website. CLC Genomics Work-
bench V5.5 was used to perform miRNA data analysis. RNA-seq data analysis
was performed by Novel Bioinformatics.
FRET Assay
FRET assays were performed as described by Hillebrand et al. (2007) with
modifications. 293 cells were transfected with CFP-MeCP2, MeCP2-YFP,
CFP-MeCP2-YFP, and CFP-MeCP280A-YFP and fixed after 48 hr. Primary
cultured cortical neurons were transfected in the same way and stimulated
with KCl for 3 hr before fixation. All quantified FRET data were collected using
a Nikon A1 laser scan confocal microscope with Plan Apo VC 603 Oil DIC N2.
CFP was excited using 457 nm laser lines, and emission was collected for
donor (482 nm) and FRET (540 nm) simultaneously, whereas YFP was excited
using 514 nm laser lines, and emission was collected at 540 nm. For each
treatment, ten cells were analyzed, and more than 2,000 signals per cell
were calculated. FRET signal was corrected by YFP and CFP bleed-through
emissions. FRET ratio was calculated with Fiji software using the emission
sensitize method.
FRET a3CFP b3YFP
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
CFP3YFP
p
Alpha-Binding Assay
The measurement was based on the ‘‘Determining Kd with an Alpha assay’’
protocol from PerkinElmer. Glutathione donor beads and Ni-chelate acceptor
beads (PerkinElmer) were used in this assay. GST-tagged mouse DGCR8 (aa
483–773) and His-tagged rat MeCP2 (aa 170–492) were overexpressed in
E. coli and purified by affinity column and HiTrap SP cation exchange column.
Gradients of untaggedmouse DGCR8 (aa 483–773) (4.5 nM–45 mM)were used
to titrate the interaction between GST-tagged DGCR8 (aa 483–773) and His-
tagged MeCP2 (aa 170–492). The concentrations of GST-DGCR8 (aa 483–
773) and His-MeCP2 (aa 170–492) used were 25 and 2.5 nM, respectively.
The concentration for both donor and acceptor beads was 10 mg ml1. The
assay was done in a solution containing 13 PBS buffer (pH 7.4), 0.2% (w/v)
BSA, 1 mM DTT, and 0.03% (v/v) Tween 20. Data were analyzed with a
one-site competition model using nonlinear regression with GraphPad Prism
software.
Dendritic Length Analysis
The length of dendritic branches in primary cultured cortical neurons was
determined as the following: EGFP-positive neurons were selected randomly
from each condition, and the total length of all protrusions was analyzed using
Neurolucida software (MBF Bioscience). All quantifications were tested with a
Student’s t test and expressed as SEM. Results were considered significant if
p < 0.05. At least three independent experiments were performed, and 10–18
neurons per transfection condition were analyzed.
Hippocampus Slice Culture and Immunostaining
The 350 mm hippocampus slices were prepared using P7 rats and cultured as
described in Zhou et al. (2006). Slices were cultured on Millicell (0.4 mm; Milli-
pore) in 6-well dishes containing 750 ml of medium and incubated in 5%CO2 at
37C. Transfection was performed with a Helios Gene Gun (Bio-Rad) at 3 DIV.
Bullets were prepared using plasmids containing 75 mg DNA and were coated
on 25 mg 1.0 mm gold particles (Bio-Rad). Slices were fixed at 9 DIV in 4%
paraformaldehyde, and GFP immunostaining was performed using anti-GFPDevelo(Invitrogen) and Alexa 488-conjugated secondary antibody (1:1,000). Slices
were also stained with DAPI (1:1,000) to visualize cell nuclei.
Slice Imaging and Analysis
Images were acquired with a Zeiss LSM5 510 laser-scanning confocal micro-
scope. Images across experiments were acquired with identical settings.
Eight-bit images were obtained using a 203 objective at 1,024 3 1,024 pixel
resolution. Images were acquired as a z stack with about 13–15 sections
(1 mm/section). Dendritic length was analyzed with Fiji software.
Spine Density Analysis
For spine density analysis, confocal z stacks of neurons in hippocampal slices
were acquired with LSM510 Laser Scanning Confocal microscope, using an
oil-immersion 603 objective lens. Images were analyzed with Fiji software.
Protrusions in direct contact with the dendrites were counted as spines, and
the average spine density was calculated as the number of spines per
10 mm dendritic length. At least 900 mm dendrites from seven or more neurons
were analyzed for each condition.
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